Document is current

Article History

Received: 27 May 2025

Revised: 7 August 2025

Accepted: 15 August 2025

First Online: 28 August 2025

Declarations

:

: All relevant regulations applicable in Germany were followed. According to local regulations, due to the non-interventional and retrospective design of the study parts, neither ethics committee approval nor registration was required.

: Written informed consent to data collection, processing and analysis was obtained from all patients of the prospective non-interventional study part prior to data collection. Patient data were anonymized and aggregated for analysis.

: OW reports honoraria for lectures from AMGEN, Berlin Chemie, Novo Nordisk, Novartis, Sanofi Aventis, Fresenius, Hexal, Akcea Therapeutics, Daiichi Sankyo and honoraria for advisory board activities from AMGEN, Sanofi Aventis, Berlin Chemie, Novartis, Hexal, Akcea Therapeutics, Daiichi Sankyo, Sobi.SG is employee of BNK Service GmbH and reports honoraria for lectures from: AstraZeneca, Daiichi Sankyo, Pfizer Pharma, Bayer Vital and honoraria for advisory board activities from Bayer Vital.KW reports honoraria for advisory board activities from Novartis.JS and DT are employees of Novartis Pharma GmbH and do not have any conflict of interest.ADL and CVV are employees of IQVIA Commercial GmbH & Co. OHG and received funding from Novartis to assist in the conduct of this study.WH does not have any conflict of interest.